BPC-157.

The TL;DR.

BPC-157 (Body Protection Compound 157) is one of the most widely discussed peptides in sports medicine and biohacking. In dozens of animal studies it has shown remarkable regenerative properties, accelerating the healing of transected tendons, torn muscles, and severe burns well-established in animal models.[2][3] It appears to work by promoting angiogenesis and upregulating growth-factor receptors at the site of injury.[4]

However, the gap between BPC-157's preclinical promise and human clinical validation is vast. As of 2026, only three small pilot studies have been conducted in humans, and it holds no FDA approval for any condition.[1] Due to the lack of human safety data, it was banned by the World Anti-Doping Agency in 2022 and restricted by the FDA in 2023 — making it legally unavailable through US compounding pharmacies.[1][5]

How it's actually used.

Before you start

• Identify the goal. Route matters: community consensus favors subcutaneous injection for musculoskeletal injuries and oral administration for gastrointestinal issues. community[12]
• Understand the regulatory status. BPC-157 cannot be legally prescribed or compounded in the US. Sourcing requires the unregulated research-chemical market.
• Check your sport's rules. BPC-157 is prohibited by WADA and most major sporting organizations.

Standard community dosing

Advanced protocols (1 mg/day) are rarely necessary and lack any safety data. Most community users report diminishing returns above 500 mcg daily. community[13]

Reconstitution math (injectable)

BPC-157 typically arrives as a lyophilized powder in a 5 mg vial. It must be reconstituted with bacteriostatic water.

Injection site selection

A major debate in the community is whether BPC-157 must be injected locally (near the injury) or systemically (e.g. abdominal fat).

• Animal data: studies show efficacy with both local and systemic administration.[2]
• Community consensus: most users prefer injecting as close to the injury site as safely possible — e.g. subcutaneous tissue over a torn hamstring — though many report success with standard abdominal injections. community[13]

Missed doses

• Missed 1 day: take the normal dose the next day. Do not double-dose.
• Missed 3+ days: resume the normal protocol. BPC-157 does not require a loading phase or titration.

Community consensus and real-world experience

In community discussions, BPC-157 is most frequently praised for its rapid effect on acute muscle strains and tendonitis. Users often report noticeable reductions in pain and inflammation within 5–10 days of starting a 500 mcg/day protocol. community[14] For chronic, degenerative conditions like severe osteoarthritis, reports are mixed — many users note pain relief while on the peptide but a return of symptoms after the cycle ends.[14] The oral-vs-injectable debate is largely settled in the community: oral formulations are considered highly effective for gut issues but ineffective for joint or tendon repair.[12]

What to eat alongside.

BPC-157 accelerates tissue repair, which means the body needs adequate building blocks to synthesize new collagen and muscle tissue.

Macronutrient adjustments

• Protein — 1.6–2.2 g/kg of body weight per day to support tissue regeneration. well-established[6]

Micronutrient adjustments

• Vitamin C — essential for collagen synthesis. Consider 500–1,000 mg daily during a healing cycle. emerging[7]
• Zinc & copper — trace minerals required for enzymatic processes in tissue repair. unknown at typical-dose recommendations specific to BPC-157.

Synergistic supplements

• Collagen peptides — 15–20 g daily, taken ~60 min before rehab exercise, provides glycine, proline, and hydroxyproline for tendon repair. emerging[8]
• Omega-3 (EPA / DHA) — 2–3 g daily to manage systemic inflammation and support cell-membrane health. well-established[9]

Protective supplements

No data available — BPC-157 has no known organ toxicity requiring specific protective supplements (e.g. liver support) based on current animal models.

What can go wrong.

Reported side effects

Drug interactions

• NSAIDs — BPC-157 has been shown in animal models to counteract the toxic effects of NSAIDs (e.g. ibuprofen) on the gut lining.[10]
• Nitric-oxide modulators — because BPC-157 interacts with the NO system, caution is advised if combining with PDE5 inhibitors (sildenafil) or high-dose arginine/citrulline. No adverse interactions have been formally documented. emerging[1]

Contraindications

Red flags

Pregnancy, lactation & fertility

No data available — BPC-157 has not been studied in pregnant or lactating women, nor has its effect on human fertility been evaluated. It should be strictly avoided in these populations.

Theoretical risks

• Pro-angiogenic concerns. Because BPC-157 promotes the formation of new blood vessels, there is a theoretical concern that it could accelerate the growth of existing tumors, which rely on angiogenesis to expand. While no animal studies have shown BPC-157 to be carcinogenic, individuals with a history of cancer should strictly avoid it. emerging[1]
• Immunogenicity. The FDA has cited the potential for immunogenicity — the body forming antibodies against the peptide — as a reason for restricting its use in compounding.[5]

What to combine it with.

Anti-pattern stacks — avoid

How to train on it.

BPC-157 is not a fat-loss or muscle-building peptide. Its role in body composition is indirect: it allows athletes to train harder, recover faster, and return from injuries that would otherwise halt their progress.

Expected trajectory

Training adjustments

• Do not mask pain. BPC-157 can rapidly reduce pain and inflammation. This is a double-edged sword. Feeling better does not mean the tissue has fully remodeled. Returning to heavy lifting too quickly can result in a catastrophic re-tear. community[14]
• Progressive loading. Tendons require mechanical load to heal properly. Once pain subsides, implement eccentric loading protocols — slow lowering phases — to stimulate collagen alignment, rather than jumping straight back into explosive or heavy concentric movements.[11]

Cut / recomp / bulk contexts

No data available — BPC-157 does not directly influence caloric partitioning, fat oxidation, or muscle hypertrophy, making it neutral across all dietary phases.

How to store it.

Light & freeze sensitivity

• Light — keep vials away from direct sunlight.
• Freeze — do not freeze the reconstituted solution.

Sourcing & legal access

• United States. As of Sept 2023, the FDA classified BPC-157 as a Category 2 bulk drug substance, meaning it cannot be legally used in compounded medications. It is no longer available through legitimate 503A or 503B compounding pharmacies.[5]
• Typical US compounding pharmacy cost. N/A — no longer legally available.
• Research-chemical market. Widely available online as a "research chemical not for human use." These products are unregulated, and independent testing frequently reveals under-dosing, impurities, or complete substitution.
• Global. Regulatory status varies, but BPC-157 is not approved as a human therapeutic in any major jurisdiction.

What to track.

Because BPC-157 is typically used for short cycles (4–8 weeks) and has no known organ toxicity in animal models, no specific markers are required for monitoring. General health monitoring is still advised.

Baseline panel

Mid-cycle panel

No data available — mid-cycle testing is not standard practice for BPC-157 due to its lack of known acute organ toxicity.

Post-cycle panel

Doctor handoff

vs. similar compounds.

When to pick BPC-157

Choose BPC-157 for localized, avascular tissue injuries — an Achilles tendon or rotator cuff tear — or for gastrointestinal healing where oral availability is decisive.

When to pick TB-500

Choose TB-500 for large muscle-belly tears or systemic, full-body inflammation. Most advanced users run BPC-157 and TB-500 concurrently — they don't compete mechanistically.

When to pick KPV

Choose KPV specifically for autoimmune-driven inflammation, mast-cell activation, or severe dermatological or gut issues where angiogenesis is not the primary goal.

What the mechanism looks like.

Mechanism of action

BPC-157 exerts its regenerative effects through a complex, pleiotropic mechanism that primarily targets the vascular and nitric-oxide systems.

The most well-documented pathway is activation of the VEGFR2–PI3K–Akt–eNOS axis. By upregulating VEGFR2, BPC-157 stimulates the production of nitric oxide via eNOS. This leads to vasodilation, vascular stability, and robust angiogenesis. emerging[1] This is particularly critical for tissues with notoriously poor blood supply, such as tendons and ligaments, where healing is rate-limited by oxygen and nutrient delivery.

In addition to angiogenesis, BPC-157 activates ERK1/2 signaling, which enhances the proliferation and migration of endothelial cells and fibroblasts. It upregulates key transcription factors — c-Fos, c-Jun, and Egr-1 — which govern the cellular repair process. emerging[1]

A unique feature of BPC-157 is its ability to upregulate growth-hormone receptors at the site of injury. In a study of transected rat Achilles tendons, BPC-157 dose- and time-dependently increased the expression of GH receptors in tendon fibroblasts at both the mRNA and protein levels. emerging[4] This localized receptor upregulation makes the injured tissue more sensitive to circulating growth hormone, accelerating repair without requiring exogenous GH.

Pharmacokinetics

No formal human pharmacokinetic studies have been published for BPC-157. unknown

In animal models, the peptide demonstrates remarkable stability in gastric juice — remaining stable for >24 hours well-established.[2] This explains its efficacy when administered orally for gastrointestinal conditions. When injected subcutaneously, the half-life is estimated to be short (minutes to hours), though downstream effects on gene transcription and receptor upregulation persist long after the peptide has been cleared from circulation. emerging

Active metabolites

No data available — the specific metabolic breakdown pathway of BPC-157 in humans has not been characterized.

The clinical-trial gap

Despite dozens of successful animal studies showing accelerated healing of fistulas, burns, and transected tendons, human data remains virtually non-existent. A 2025 scoping review identified only three pilot studies involving human subjects.[1]

A Phase 2 RCT for acute hamstring strain (NCT07437547) is currently recruiting, with primary completion estimated for 2027.

Open questions

Frequently asked.

Where it stands, by jurisdiction.

Last verified · May 17, 2026

Is BPC-157 for you?

What we cited.